Advertorial

Porton Pharma Solutions and Codexis launch global partnership

2
SHARES

Codexis, Inc. (NASDAQ: CDXS) and Porton Pharma Solutions, Ltd. (SZSE: 300363) announce a strategic collaboration to deploy Codexis’ world-leading biocatalyst technology within Porton’s global custom intermediate and active pharmaceutical ingredients (API) development and manufacturing business…

Global-handshake

The partnership will accelerate the creation and commercialisation of new, low-cost, sustainable manufacturing processes, exploiting the benefits of biocatalysts to a growing number of the world’s small molecule pharmaceuticals.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Under the terms of the collaboration, Codexis will license core elements of its biocatalyst technologies to Porton, including its proprietary biocatalyst libraries, high-throughput screening and enzyme manufacturing know-how. Codexis will also provide preferential access to its CodeEvolver® protein engineering platform technology for the creation of new biocatalytic process solutions. Porton will install new operations to drive adoption and optimal application of these biocatalyst technologies into its custom contract development and manufacturing (CDMO) offerings to global pharmaceutical customers. Additionally, Porton pledges financial commitments to utilise Codexis’ CodeEvolver® protein engineering platform technology.

The partnership reinforces the benefits of reduced costs, enhanced sustainability and improved product quality that biocatalysts can deliver to the manufacturing of the world’s small molecule pharmaceuticals. These benefits are already impacting a growing set of the world’s drug manufacturing processes and have earned Codexis three U.S. EPA Presidential Green Chemistry Challenge awards for its biocatalysts’ contributions in these commercial-scale drug manufacturing innovations.

“Technological leadership is central to our strategy to grow and deliver value to our pharmaceutical clients around the globe,” said Oliver Ju, chairman and CEO at Porton Pharma Solutions. “We believe that biocatalysis is the most impactful technology to improve the future of pharmaceutical manufacturing, and there is not a more capable player to partner with than Codexis.”

“We are delighted to establish this unique partnership with Porton,” said John Nicols, president and CEO of Codexis. “Given Porton’s significant and fast-growing presence as a leading global CDMO, we will now be able to reach a greater share of the world’s pharmaceutical manufacturing market.”

Share via
Share via